mianserin has been researched along with Neoplasms in 23 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed an open-label single-institution phase II trial of mirtazapine (15-30 mg by mouth [po] every day [qd]), a tetracyclic antidepressant that may lead to weight gain, for 8 weeks in nondepressed patients with cancer-related cachexia/anorexia (CRCA)." | 9.14 | Phase II trial of mirtazapine for cancer-related cachexia and anorexia. ( Burman, D; Riechelmann, RP; Rodin, G; Tannock, IF; Zimmermann, C, 2010) |
| "The purpose of the present paper was to evaluate the effectiveness of mirtazapine orally disintegrating tablets for nausea and sleep disturbance, which are common and distressing symptoms of cancer." | 9.13 | Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. ( Kim, JM; Kim, KM; Kim, KS; Kim, SW; Kim, YC; Shin, IS; Yang, SJ; Yoon, JS, 2008) |
| "We conducted a nested case-control study to evaluate the association between risk of cancer and mirtazapine use in depression patients in Taiwan." | 7.79 | Does use of tetracyclic antidepressant-mirtazapine reduce cancer risk in depression patients? ( Chang, SN; Chang, YJ; Kao, CH; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC, 2013) |
| "Mirtazapine and olanzapine are easy-to-use psychiatric drugs with potent antinausea effects." | 7.74 | Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. ( Foley, KF; Kast, RE, 2007) |
| "Mirtazapine is a noradrenergic and specific serotonergic antidepressant(NaSSA)." | 6.74 | [Efficacy of mirtazapine for appetite loss and nausea of the cancer patient--from clinical experience in Memorial Sloan-Kettering Cancer Center]. ( Ito, T; Okubo, Y; Roth, A, 2009) |
| "Depression is a major complication of cancer." | 6.66 | Efficacy and safety of mianserin in the treatment of depression of women with cancer. ( Costa, D; Mogos, I; Toma, T, 1985) |
| "Pruritus is a relatively rare but distressing symptom associated with cholestasis, renal failure, and malignancies." | 5.32 | Mirtazapine for pruritus. ( Andresen, S; Davis, MP; Frandsen, JL; Taylor, S; Walsh, D, 2003) |
| "We performed an open-label single-institution phase II trial of mirtazapine (15-30 mg by mouth [po] every day [qd]), a tetracyclic antidepressant that may lead to weight gain, for 8 weeks in nondepressed patients with cancer-related cachexia/anorexia (CRCA)." | 5.14 | Phase II trial of mirtazapine for cancer-related cachexia and anorexia. ( Burman, D; Riechelmann, RP; Rodin, G; Tannock, IF; Zimmermann, C, 2010) |
| "The purpose of the present paper was to evaluate the effectiveness of mirtazapine orally disintegrating tablets for nausea and sleep disturbance, which are common and distressing symptoms of cancer." | 5.13 | Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. ( Kim, JM; Kim, KM; Kim, KS; Kim, SW; Kim, YC; Shin, IS; Yang, SJ; Yoon, JS, 2008) |
| "This study aimed to compare the effectiveness of mirtazapine and imipramine on not only the distressing symptoms of cancer patients such as pain, nausea, vomiting, appetite loss, and sleep disturbances but also depressive and anxiety symptoms." | 5.13 | Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. ( Akbiyik, DI; Alkis, N; Cankurtaran, ES; Ozalp, E; Soygur, H; Turhan, L, 2008) |
| "We conducted a nested case-control study to evaluate the association between risk of cancer and mirtazapine use in depression patients in Taiwan." | 3.79 | Does use of tetracyclic antidepressant-mirtazapine reduce cancer risk in depression patients? ( Chang, SN; Chang, YJ; Kao, CH; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC, 2013) |
| "Mirtazapine and olanzapine are easy-to-use psychiatric drugs with potent antinausea effects." | 3.74 | Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. ( Foley, KF; Kast, RE, 2007) |
| "It involved 88 terminally ill cancer patients from University of Malaya Medical Centre, Kuala Lumpur, Malaysia." | 2.79 | Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study. ( Boks, MP; de Wit, NJ; Ng, CG; Roes, KC; Sulaiman, AH; Tan, SB; Zainal, NZ, 2014) |
| "Mirtazapine is a noradrenergic and specific serotonergic antidepressant(NaSSA)." | 2.74 | [Efficacy of mirtazapine for appetite loss and nausea of the cancer patient--from clinical experience in Memorial Sloan-Kettering Cancer Center]. ( Ito, T; Okubo, Y; Roth, A, 2009) |
| "Depression is quite common among cancer patients." | 2.73 | An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients. ( Elbi, H; Ersoy, MA; Noyan, AM, 2008) |
| "Many cancer patients of the "Service des Maladies Sanguines et Tumorales" of Hôpital Paul-Brousse, Villejuif, are psychologically studied by: the objective and quantified Szondi test, and in the case a depressive syndrome clinical diagnosis is confirmed, this state is quantified by a quintile questionnaire requiring 25 "yes or no" answers (determined by five grades and five stages), in case an inhibition or/and hysteric component is found, the subjects are submitted to the care of a psychoanalyst." | 2.66 | A comparative trial of a MAOI, iproniazide, and a polycyclic agent, mianserine, for the search of the most rapidly and frequently active treatment of depressive syndromes in an oncology service. ( Brienza, S; de Vassal, F; Fréchet, M; Gastiaburu, J; Lopez, MD; Mathé, G, 1987) |
| "Depression is a major complication of cancer." | 2.66 | Efficacy and safety of mianserin in the treatment of depression of women with cancer. ( Costa, D; Mogos, I; Toma, T, 1985) |
| "In cases of malignancy that are refractive to treatment, other therapies have been found to be effective for paraneoplastic itch, including selective serotonin reuptake inhibitors, mirtazapine, gabapentin, thalidomide, opioids, aprepitant, and histone deacetylase inhibitors." | 2.53 | Paraneoplastic Itch Management. ( Rowe, B; Yosipovitch, G, 2016) |
| "Advanced cancer patients are polysymptomatic and often receive multiple medications for symptom relief." | 2.41 | Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project. ( Davis, MP; Khawam, E; Lagman, R; Pozuelo, L, 2002) |
| "Mirtazapine was administered to 50 cancer patients with digestive symptoms in palliative care, and the data were retrospectively examined." | 1.40 | [Effectiveness of mirtazapine for digestive symptoms in palliative care - retrospective study of 50 cases]. ( Imai, E; Nishimura, D; Shibahara, H; Tokura, Y; Uematsu, N, 2014) |
| "One hundred sixty-five patients with cancer, consecutively admitted to the Oncology Division of San Camillo-Forlanini Hospital, were recruited to the study." | 1.33 | Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division. ( Biondi, M; Cairoli, F; Costantini, A; Ferrarese, G; Pasquini, M; Picardi, A; Sternberg, C, 2006) |
| "Pruritus is a relatively rare but distressing symptom associated with cholestasis, renal failure, and malignancies." | 1.32 | Mirtazapine for pruritus. ( Andresen, S; Davis, MP; Frandsen, JL; Taylor, S; Walsh, D, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (56.52) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, LM | 1 |
| Lin, MC | 1 |
| Liang, JA | 1 |
| Chang, YJ | 1 |
| Chang, SN | 1 |
| Sung, FC | 1 |
| Muo, CH | 1 |
| Kao, CH | 1 |
| Raddin, RS | 1 |
| Park, EM | 1 |
| Hamer, RM | 1 |
| Nelson, KM | 1 |
| Mayer, DK | 1 |
| Rosenstein, DL | 1 |
| Bernard, SA | 1 |
| Ng, CG | 1 |
| Boks, MP | 1 |
| Roes, KC | 1 |
| Zainal, NZ | 1 |
| Sulaiman, AH | 1 |
| Tan, SB | 1 |
| de Wit, NJ | 1 |
| Shibahara, H | 1 |
| Uematsu, N | 1 |
| Imai, E | 1 |
| Tokura, Y | 1 |
| Nishimura, D | 1 |
| Uzawa, K | 1 |
| Kasamatsu, A | 1 |
| Shimizu, T | 1 |
| Saito, Y | 1 |
| Baba, T | 1 |
| Sakuma, K | 1 |
| Fushimi, K | 1 |
| Sakamoto, Y | 1 |
| Ogawara, K | 1 |
| Shiiba, M | 1 |
| Tanzawa, H | 1 |
| Rowe, B | 1 |
| Yosipovitch, G | 1 |
| Ito, T | 1 |
| Okubo, Y | 1 |
| Roth, A | 1 |
| Riechelmann, RP | 1 |
| Burman, D | 1 |
| Tannock, IF | 1 |
| Rodin, G | 1 |
| Zimmermann, C | 1 |
| Davis, MP | 3 |
| Kirkova, J | 1 |
| Lagman, R | 2 |
| Walsh, D | 2 |
| Karafa, M | 1 |
| Van Gool, AR | 1 |
| Bannink, M | 1 |
| Stronks, DL | 1 |
| Vos, MS | 1 |
| Frandsen, JL | 1 |
| Andresen, S | 1 |
| Taylor, S | 1 |
| Khawam, E | 1 |
| Pozuelo, L | 1 |
| Raji, MA | 2 |
| Pasquini, M | 1 |
| Biondi, M | 1 |
| Costantini, A | 1 |
| Cairoli, F | 1 |
| Ferrarese, G | 1 |
| Picardi, A | 1 |
| Sternberg, C | 1 |
| Ito, H | 1 |
| Harada, D | 1 |
| Hayashida, K | 1 |
| Ishino, H | 1 |
| Nakayama, K | 1 |
| Kast, RE | 1 |
| Foley, KF | 1 |
| Barnum, PD | 1 |
| Freeman, J | 1 |
| Markowitz, AB | 1 |
| Ersoy, MA | 1 |
| Noyan, AM | 1 |
| Elbi, H | 1 |
| Kim, SW | 1 |
| Shin, IS | 1 |
| Kim, JM | 1 |
| Kim, YC | 1 |
| Kim, KS | 1 |
| Kim, KM | 1 |
| Yang, SJ | 1 |
| Yoon, JS | 1 |
| Cankurtaran, ES | 1 |
| Ozalp, E | 1 |
| Soygur, H | 1 |
| Akbiyik, DI | 1 |
| Turhan, L | 1 |
| Alkis, N | 1 |
| Theobald, DE | 1 |
| Kirsh, KL | 1 |
| Holtsclaw, E | 1 |
| Donaghy, K | 1 |
| Passik, SD | 1 |
| Mathé, G | 1 |
| Lopez, MD | 1 |
| Fréchet, M | 1 |
| de Vassal, F | 1 |
| Brienza, S | 1 |
| Gastiaburu, J | 1 |
| Costa, D | 1 |
| Mogos, I | 1 |
| Toma, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Parallel-group, Double-blind, Placebo-controlled Study of Methylphenidate as an Add on Therapy for Mirtazapine in the Treatment of Major Depressive Disorder in Cancer Patients Under Palliative Care[NCT01497548] | Phase 3 | 120 participants (Anticipated) | Interventional | 2011-03-31 | Recruiting | ||
| Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients[NCT02650544] | Phase 2 | 236 participants (Anticipated) | Interventional | 2015-12-31 | Active, not recruiting | ||
| Randomized, Double-blind Clinical Trial of the Use of Mirtazapine Versus Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.[NCT03283488] | Phase 2 | 52 participants (Actual) | Interventional | 2019-03-26 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for mianserin and Neoplasms
| Article | Year |
|---|---|
Paraneoplastic Itch Management.
Topics: Acantholysis; Acanthosis Nigricans; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Apre | 2016 |
Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Drug Interactions; Humans; Mianserin; | 2002 |
9 trials available for mianserin and Neoplasms
| Article | Year |
|---|---|
Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study.
Topics: Academic Medical Centers; Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and St | 2014 |
[Efficacy of mirtazapine for appetite loss and nausea of the cancer patient--from clinical experience in Memorial Sloan-Kettering Cancer Center].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Appetite; Appetite Stimulants; Female; Hospit | 2009 |
Phase II trial of mirtazapine for cancer-related cachexia and anorexia.
Topics: Aged; Aged, 80 and over; Anorexia; Antidepressive Agents, Tricyclic; Appetite; Body Weight; Cachexia | 2010 |
An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antidepressive Agents, Tricyclic; Depressive Disorder; | 2008 |
Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression.
Topics: Adjustment Disorders; Administration, Oral; Adult; Aged; Antidepressive Agents, Tricyclic; Depressiv | 2008 |
Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine.
Topics: Adaptation, Psychological; Adjustment Disorders; Adrenergic alpha-Antagonists; Adult; Antidepressive | 2008 |
An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms.
Topics: Antidepressive Agents, Tricyclic; Cross-Over Studies; Depression; Dose-Response Relationship, Drug; | 2002 |
An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms.
Topics: Antidepressive Agents, Tricyclic; Cross-Over Studies; Depression; Dose-Response Relationship, Drug; | 2002 |
An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms.
Topics: Antidepressive Agents, Tricyclic; Cross-Over Studies; Depression; Dose-Response Relationship, Drug; | 2002 |
An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms.
Topics: Antidepressive Agents, Tricyclic; Cross-Over Studies; Depression; Dose-Response Relationship, Drug; | 2002 |
A comparative trial of a MAOI, iproniazide, and a polycyclic agent, mianserine, for the search of the most rapidly and frequently active treatment of depressive syndromes in an oncology service.
Topics: Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depressive Disorder; Female; Humans; Ipr | 1987 |
Efficacy and safety of mianserin in the treatment of depression of women with cancer.
Topics: Adult; Aged; Clinical Trials as Topic; Depression; Dibenzazepines; Female; Humans; Mianserin; Middle | 1985 |
12 other studies available for mianserin and Neoplasms
| Article | Year |
|---|---|
Does use of tetracyclic antidepressant-mirtazapine reduce cancer risk in depression patients?
Topics: Adult; Age Factors; Aged; Antidepressive Agents; Case-Control Studies; Chi-Square Distribution; Como | 2013 |
A pilot study to evaluate symptom-oriented selection of antidepressants in patients with cancer.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depressive D | 2014 |
[Effectiveness of mirtazapine for digestive symptoms in palliative care - retrospective study of 50 cases].
Topics: Adult; Aged; Aged, 80 and over; Feeding and Eating Disorders; Female; Humans; Male; Mianserin; Middl | 2014 |
Suppression of metastasis by mirtazapine via restoration of the Lin-7C/β-catenin pathway in human cancer cells.
Topics: Adrenergic alpha-Antagonists; Animals; beta Catenin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cel | 2014 |
Intolerance to mirtazapine in advanced cancer.
Topics: Aged; Antidepressive Agents; Depressive Disorder; Disorders of Excessive Somnolence; Female; Humans; | 2011 |
Re: Mirtazapine in cancer patients.
Topics: Antidepressive Agents, Tricyclic; Depression; Female; Humans; Male; Mianserin; Middle Aged; Mirtazap | 2003 |
Mirtazapine for pruritus.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Cholestasis; Female; Histamine H1 Antagon | 2003 |
Management of chemotherapy-induced side-effects.
Topics: Antiemetics; Antineoplastic Agents; Histamine H1 Antagonists; Humans; Mianserin; Mirtazapine; Nausea | 2005 |
Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Citalopram; Depressive D | 2006 |
[Psychiatry and sleep disorders--delirium].
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; I | 2006 |
Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Cachexia; Humans; Mianserin; Mirtazapine; Nause | 2007 |
Mirtazapine for depression and comorbidities in older patients with cancer.
Topics: Aged; Antidepressive Agents, Tricyclic; Antiemetics; Comorbidity; Depression; Humans; Mianserin; Mir | 2007 |